# OnCo record dawna-1 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/dawna-1/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "dawna-1", "NCT03927456" ;
  schema:name "DAWNA-1"@en ;
  schema:description "The trial that made dalpiciclib the first Chinese CDK4/6 inhibitor approved, more than doubling the time before breast cancer grew when added to fulvestrant."@en ;
  schema:url <https://onco.cc/trials/dawna-1/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03927456>, <https://doi.org/10.1038/s41591-021-01562-9> ;
  onco:status "positive" ;
  onco:tag "china" ;
  onco:phase "3" ;
  schema:startDate "2019-06-13" ;
  onco:cancers <https://onco.cc/cancers/breast-hr-positive/> ;
  onco:technologies <https://onco.cc/technologies/cdk46-inhibitor/> ;
  onco:targets <https://onco.cc/targets/cdk4-6/> ;
  onco:drugs <https://onco.cc/drugs/dalpiciclib/>, <https://onco.cc/drugs/fulvestrant/> ;
  onco:companies <https://onco.cc/companies/hengrui/> ;
  onco:institutions <https://onco.cc/institutions/cams-cancer-hospital/> ;
  onco:people <https://onco.cc/people/xu-binghe/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-dawna-1-nat-med-2021/> .